

- **Full Name:** Everett Vokes, MD
- **Current Position & Affiliation:** John E. Ultmann Distinguished Service Professor
Chairman, Department of Medicine

Physician-in-Chief, University of Chicago Medicine
and Biological Sciences
- **Country:** United States

• **Educational Background:**

University of Bonn Medical School, West Germany	MD	06/1980	Medicine
Ravenswood Hospital, Chicago, IL		06/1980	Internal Medicine
University of Southern California Los Angeles County Hospital, Los Angeles, CA		06/1982	Internal Medicine
University of Chicago, Chicago, IL		06/1983	Hematology and Oncology

• **Professional Experience:**

- 2010– Physician-in-Chief, University of Chicago Medical Center
- 2009– Chairman, Department of Medicine, University of Chicago
- 2009–2010 Interim Dean and CEO, Biological Sciences Division & Pritzker School of Medicine, University of Chicago
- 2005–2009 Vice-Chair for Clinical Research, Dept. of Medicine, University of Chicago
- 2004–2009 Deputy Director, University of Chicago Cancer Research Center
- 1998–2009 Section Chief, Hematology/Oncology, University of Chicago
- 1997–1998 Member, Council of the University Senate
- 1995– Professor, Dept. of Medicine, Section of Hematology/ Oncology and Dept. of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine
- 1994–1998 Associate Director (Clinical Affairs), University of Chicago Cancer Research Center
- 1995–2009 Program Co-Leader, Experimental and Clinical Therapeutics, Core, University of Chicago Cancer Research Center
- 1995–1998 Core Director, Protocol and Data Management Office, University of Chicago Cancer Research Center
- 1991–1994 Chairman, Clinical Trials Review Committee, University of Chicago Cancer Research Center
- 1991–1995 Program Leader, Clinical Investigations, Core Director, Biostatistics and Data Management, University of Chicago Cancer Research Center
- 1991–1995 Associate Professor, Dept. of Medicine, Sect. of Hematology and Oncology and Dept. of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine
- 1989–1998 Director of Clinical Research, Sect. of Hematology and Oncology, University of Chicago

- 1989–1991 Assistant Professor, Dept. of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine
- 1987–1991 Assistant Professor, Dept. of Medicine, Section of Hematology and Oncology, University of Chicago Pritzker School of Medicine
- 1986–1989 Attending Member, Dept. of Medicine, Division of Hematology and Oncology, Michael Reese Hospital and Medical Center
- 1986–1988 Associate, Dept. of Medicine, Division of Hematology and Oncology, Michael Reese Hospital and Medical Center
- 1986– Director, Head and Neck Oncology Program, University of Chicago
- 1986–1987 Instructor, Dept. of Medicine, Joint Sect. of Hematology and Oncology, University of Chicago Pritzker School of Medicine and Michael Reese Hospital

• Professional Organizations:

- Member, Association of American Physicians (AAP)
- Member, American Society for Clinical Investigation (ASCI)
- Fellow, American College of Physicians
- Fellow, American College of Chest Physicians
- Fellow, American Society of Clinical Oncology
- Member, American Association for Cancer Research
- Member, American Association for the Advancement of Science
- Member, European Society for Medical Oncology
- Member, International Association for the Study of Lung Cancer

• Main Scientific Publications:

1. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. *J Clin Oncol*, 39(7): 723-733, 2021.
2. Juloori A, Vokes EE. Beyond PACIFIC: Uncharted Waters. *J Thorac Oncol*, 16(5): 715-718, 2021.
3. Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, de Souza JA, Vokes EE. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. *Oral Oncol*, 114, March 2021.
4. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylor GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. *N Engl J Med*, 386(21): 1973-1985, 2022.

5. Vokes EE. 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. *J Clin Oncol*, 40(25): 2859-2862, 2022.
6. Dolezal JM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Cody B, Mansfield AS, Rakshit S, Bansal R, Bois MC, Bungum AO, Schulte JJ, Vokes EE, Garassino MC, Husain AN, Pearson AT. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. *Nat Commun*, 13(1): 6572, 2022.
7. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. *N Engl J Med*, 388(6): 489-498, 2023.
8. Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, Heymach J, Bonner J, Kuzma C, Waqar S, Petty W, Stinchcombe TE, Bradley JD, Vokes E. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. *J Clin Oncol*, 41(13): 2394-2402, 2023.
9. Rosenberg AJ, Vokes EE. “Timing is Everything”: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma. *Ann Oncol*, 34(3): 213-214, 2023.